EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigation of GPR137C as a promising novel marker for the progression of prostate cancer through G4 screen and bioinformatics analyses

Yue Hou, Haowen Lu, Saisai Chen, Likai Mao, Xuan Huang, Feng Xu, Chuanjun Shu

Frontiers in Immunology · 2025

DOI: 10.3389/fimmu.2025.1576835 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, 2025. Verfasst von Yue Hou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Military Medical Innovation Center, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor, G-Quadruplexes, Receptors, G-Protein-Coupled. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Prostate cancer (PCa) remains the fifth leading cause of male cancer mortality, necessitating novel biomarkers and therapeutic targets.

Methods

Through BG4 ChIP-seq profiling in PCa cells, we identified promoter G-quadruplex (G4) structures in prognosis-associated genes, with GPR137C exhibiting a functional G4 in its promoter.

Results

This G4 structure facilitates promoter hypomethylation to activate GPR137C transcription. Moreover, GPR137C promotes tumor microenvironment remodeling by enhancing immune cell infiltration, thereby driving PCa progression. Disscussion This study establishes promoter G4s as epigenetic regulators in PCa while proposing GPR137C as both a prognostic biomarker and a therapeutic nexus for GPCR-targeted drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBiomarkers, TumorG-QuadruplexesReceptors, G-Protein-CoupledHumansMaleDisease ProgressionPromoter Regions, GeneticComputational BiologyGene Expression Regulation, NeoplasticCell Line, TumorDNA MethylationEpigenesis, GeneticTumor MicroenvironmentPrognosisAnimals

Stichwörter der Autor:innen

G-quadruplexGPCRs de-orphanizationGPR137Cdrugsprostate cancer

Substanzen

Biomarkers, TumorReceptors, G-Protein-Coupled

Autor:innen und Institutionen

  • Military Medical Innovation Center, Fourth Military Medical University, Xi'an, China.
  • Department of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, Jiangsu, China.
  • Reproductive Medical Center, Jinling Hospital Affiliated to Medical School of Nanjing University, Nanjing, Jiangsu, China.
  • Department of Urology, Jinhu County Peoples Hospital, Huai'an, Jiangsu, China.
  • Department of Bioinformatics, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, China.

Zitieren

APA

Hou, Y., Lu, H., Chen, S., Mao, L., Huang, X., Xu, F., & Shu, C. (2025). Investigation of GPR137C as a promising novel marker for the progression of prostate cancer through G4 screen and bioinformatics analyses. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1576835

Vancouver

Hou Y, Lu H, Chen S, Mao L, Huang X, Xu F, et al. Investigation of GPR137C as a promising novel marker for the progression of prostate cancer through G4 screen and bioinformatics analyses. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1576835

BibTeX
@article{Hou2025,
  author = {Hou, Yue and Lu, Haowen and Chen, Saisai and Mao, Likai and Huang, Xuan and Xu, Feng and Shu, Chuanjun},
  title = {Investigation of GPR137C as a promising novel marker for the progression of prostate cancer through G4 screen and bioinformatics analyses},
  journal = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1576835}
}
Kostenlos starten →